Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy

INTRODUCTION: Drotrecogin alfa (activated) (DrotAA) is licensed in the United States and the European Union for the treatment of severe sepsis with multiple organ failure. Patients with severe sepsis on renal replacement therapy (RRT), who typically receive additional anticoagulation to prevent circ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Camporota, Luigi, Corno, Eleonora, Menaldo, Eleonora, Smith, John, Lei, Katie, Beale, Richard, Wyncoll, Duncan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2008
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2646328/
https://ncbi.nlm.nih.gov/pubmed/19094233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc7163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados